Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen, Inc. | -0.57% | 283.29 | 1.5% | $876.09m | |
| GILD | Gilead Sciences, Inc. | -0.02% | 87.96 | 1.0% | $686.29m | |
| MRNA | Moderna, Inc. | -1.36% | 173.54 | 0.0% | $642.89m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.06% | 747.47 | 2.6% | $489.87m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.82% | 311.81 | 1.9% | $475.10m | |
| BIIB | Biogen, Inc. | -0.44% | 291.47 | 1.8% | $409.07m | |
| ILMN | Illumina, Inc. | -3.69% | 205.98 | 3.2% | $225.66m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -1.27% | 102.22 | 4.2% | $161.73m | |
| BNTX | BioNTech SE | -3.05% | 161.62 | 0.0% | $160.60m | |
| AXSM | Axsome Therapeutics, Inc. | -2.63% | 75.26 | 1.6% | $141.48m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -6.51% | 2.01 | 0.7% | $140.51m | |
| MRTX | Mirati Therapeutics, Inc. | -22.89% | 71.52 | 1.6% | $125.68m | |
| HALO | Halozyme Therapeutics, Inc. | 0.79% | 56.38 | 18.4% | $81.14m | |
| NVAX | Novavax, Inc. | -4.71% | 16.78 | 75.3% | $80.38m | |
| IMGO | Imago BioSciences, Inc. | 0.00% | 35.86 | 0.0% | $59.53m |
Company Profile
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.